Gait Disorders in Patients With Cognitive Decline

NCT03399591 | Unknown

• 1 other identifier: 6963
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The prevalence of neurodegenerative diseases will increase over the next decades driven by ageing population. It seems important to develop reliable, replicable and accessible diagnostic tools. This is a prospective study whose objective is to study the spatio-temporal parameters of gait in patients with Alzheimer's and Lewy body diseases. 64 patients were included in this study. A comparison of the two pathologies was conducted, followed by an analysis based on four groups (mild, severe Alzheimer's disease, mild, severe Lewy body disease) and a study of the severity of the diseases. To study these parameters, we used the Gaitrite treadmill. The analysis of spatio-temporal parameters of walking in Alzheimer's disease and Lewy body disease enables to identify discriminating variables between the two pathologies. The probability of suffering from an Alzheimer's disease decreases with the pace increase but increases with variations in length of the step, and with the rotation of the foot. While the probability of suffering from Lewy body disease increases with the pace, variations in the step duration, and the duration of double support. These results are interesting but do not allow to establish a diagnostic score for these two diseases. The monitoring of the variations of these parameters at individual level would probably be more relevant and would enable to detect dual pathologies.

Conditions

Gait Disorders, Neurologic

Keywords

Gait Disorders; Spatio-temporal parameters of walking; Alzheimer's disease; Lewy body disease

Outcome Measures

Primary Outcomes (1)

• walking test

  1 hour after inclusion

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient over the age of 50 with a gait disorder

You may qualify if:

• Patient over 50
• Hospitalized patient in day hospital
• Patient with an etiological diagnosis of his cognitive disorder
• Patient having a neuropsychological assessment
• Patient able to walk without technical help
• Patient having agreed to participate in the study

You may not qualify if:

• \- Refusal to participate in the study

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Gériatrie Hôpital de la Robertsau

Strasbourg, 67000, France

RECRUITING

MeSH Terms

Conditions

Gait Disorders, Neurologic; Mobility Limitation; Alzheimer Disease; Lewy Body Disease

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Dementia; Brain Diseases; Central Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies

Study Officials

• Jérémie PERISSE, MD

  University Hospital, Strasbourg, France

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jérémie PERISSE, MD

CONTACT

33 3 88 11 55 11; jeremie.perisse@chru-strasbourg.fr

Candice Muller, MD

CONTACT

33 3 88 11 55 11; candice.muller@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 8, 2018
• First Posted: January 16, 2018
• Study Start: May 2, 2017
• Primary Completion: March 1, 2019
• Study Completion: March 1, 2019
• Last Updated: July 6, 2018

Record last verified: 2018-01

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)